Biogen 2Q Revenues: $3.1 billion (+6%) 2Q Earnings: $863 million (-18%) YTD Revenues: $5.9 billion (+5%) YTD Earnings: $1.6 billion (-20%) Comments: Growth was driven by MS revenues, which increased 5%. This included a 13% increase in TECFIDERA to $1.1 billon. SPINRAZA revenues grew to $203 million and BENEPALIT revenues increased to $89 million in the quarter. Avonex sales were down 8% to $691 million. Tysabri sales were flat at $496 million. Plegridy sales were $133 million, up 8%. Biosim...